TITLE

The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations

AUTHOR(S)
Citro, Valentina; Cammisa, Marco; Liguori, Ludovica; Cimmaruta, Chiara; Lukas, Jan; Cubellis, Maria Vittoria; Andreotti, Giuseppina
PUB. DATE
December 2016
SOURCE
International Journal of Molecular Sciences;Dec2016, Vol. 17 Issue 12, p2010
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Fabry disease is caused by mutations in the GLA gene and is characterized by a large genotypic and phenotypic spectrum. Missense mutations pose a special problem for graduating diagnosis and choosing a cost-effective therapy. Some mutants retain enzymatic activity, but are less stable than the wild type protein. These mutants can be stabilized by small molecules which are defined as pharmacological chaperones. The first chaperone to reach clinical trial is 1-deoxygalactonojirimycin, but others have been tested in vitro. Residual activity of GLA mutants has been measured in the presence or absence of pharmacological chaperones by several authors. Data obtained from transfected cells correlate with those obtained in cells derived from patients, regardless of whether 1-deoxygalactonojirimycin was present or not. The extent to which missense mutations respond to 1-deoxygalactonojirimycin is variable and a reference table of the results obtained by independent groups that is provided with this paper can facilitate the choice of eligible patients. A review of other pharmacological chaperones is provided as well. Frequent mutations can have residual activity as low as one-fourth of normal enzyme in vitro. The reference table with residual activity of the mutants facilitates the identification of non-pathological variants.
ACCESSION #
120516833

 

Related Articles

  • Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.  // Orphanet Journal of Rare Diseases;7/12/2016, Vol. 11, p1 

    A correction to the article "Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment" is presented.

  • A case of Fabry nephropathy with histological features of oligonephropathy. Nishida, Masashi; Kosaka, Kitaro; Hasegawa, Koh; Nishikawa, Kousuke; Itoi, Toshiyuki; Tsukimura, Takahiro; Togawa, Tadayasu; Sakuraba, Hitoshi; Hamaoka, Kenji // European Journal of Pediatrics;Aug2014, Vol. 173 Issue 8, p1111 

    Newborn screening studies indicate the expected high incidence of later-onset Fabry disease with silent Fabry nephropathy while, with recent improved clinical care of premature infants, children with congenital oligonephropathy caused by premature embryonal development of the kidney are thought...

  • Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease. Citro, Valentina; Peña-García, Jorge; den-Haan, Helena; Pérez-Sánchez, Horacio; Del Prete, Rosita; Liguori, Ludovica; Cimmaruta, Chiara; Lukas, Jan; Cubellis, Maria Vittoria; Andreotti, Giuseppina // PLoS ONE;10/27/2016, Vol. 11 Issue 10, p1 

    Personalized therapies are required for Fabry disease due to its large phenotypic spectrum and numerous different genotypes. In principle, missense mutations that do not affect the active site could be rescued with pharmacological chaperones. At present pharmacological chaperones for Fabry...

  • Fabry disease: experience of screening dialysis patients for Fabry disease. Kusano, Eiji; Saito, Osamu; Akimoto, Tetsu; Asano, Yasushi // Clinical & Experimental Nephrology;Apr2014, Vol. 18 Issue 2, p269 

    The prevalence rate for Fabry disease is conventionally considered to be 1 case in 40,000; however, due to increased screening accuracy, reports now suggest that prevalence is 1 case in 1,500 among male children, and it is likely that the clinical importance of the condition will increase in the...

  • Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease. Marchesan, D.; Cox, T. M.; Deegan, P. B. // Current Medical Literature: Lysosomal Storage Disease;2013, Vol. 11 Issue 2, p58 

    A review of the article "Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease," by D. Marchesan, T. M. Cox, and P. B. Deegan, which appeared in the periodical "Journal of Inherited Metabolic Disease" in 2012, is presented.

  • Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones. Cammisa, Marco; Correra, Antonella; Andreotti, Giuseppina; Cubellis, Maria Vittoria // Orphanet Journal of Rare Diseases;2013, Vol. 8 Issue 1, p1 

    Fabry_CEP is a user-friendly web-application designed to help clinicians Choose Eligible Patients for the therapy with pharmacological chaperones. It provides a database and a predictive tool to evaluate the responsiveness of lysosomal alpha-galactosidase mutants to a small molecule drug, namely...

  • Enzyme replacement therapy for Anderson-Fabry disease. MacDermot, Kay // Current Medical Literature: Lysosomal Storage Disease;2013, Vol. 11 Issue 3, p84 

    The author reflects on the results of a study by P. Nascimento and colleagues on six clinical trials assessing the effectiveness of enzyme replacement therapy (ERT) with Anderson-Fabry disease, which found that trials should include adequate sample sizes to accurately assess the efficacy of ERT.

  • Renal complications of Fabry disease in children. Najafian, Behzad; Mauer, Michael; Hopkin, Robert; Svarstad, Einar // Pediatric Nephrology;May2013, Vol. 28 Issue 5, p679 

    Fabry disease is an X-linked α-galactosidase A deficiency, resulting in accumulation of glycosphingolipids, especially globotriaosylceramide, in cells in different organs in the body. Renal failure is a serious complication of this disease. Fabry nephropathy lesions are present and progress...

  • A case study of a 59-year-old male with a cardiac variant of Anderson–Fabry disease. Jackson, Sarah; Ashton, Lisa // British Journal of Cardiac Nursing;Jan2015, Vol. 10 Issue 1, p26 

    Anderson–Fabry disease is a rare X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A, affecting around 1 in 100,000 births. Waste products build up within cells throughout the body, affecting the heart, nervous system, skin, eyes and kidneys. In...

  • Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data. Engelen, M. A.; Brand, E.; Baumeister, T. B. // Current Medical Literature: Lysosomal Storage Disease;2013, Vol. 11 Issue 2, p65 

    A review of the article "Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data," by M. A. Engelen in the "British Medical Journal Open" (BMJ) in 2012.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics